Literature DB >> 23831989

[Venous thromboembolism prophylaxis for urological operations].

G Lümmen1, C Fischer.   

Abstract

Deep vein thrombosis and the associated danger of pulmonary embolism are two manifestations of one disease. The frequency of deep vein thrombosis in operative medicine without medicinal prophylaxis varies between 14% and 32% and the resulting pulmonary embolism rate is approximately 0.8-6.2%. When deep vein thrombosis is suspected, a diagnostic clarification is carried out by determination of D-dimer levels, compression sonography of the veins and if necessary phlebography. When pulmonary embolism is suspected, the diagnostics are extended to computed tomography angiography (CTA) and if necessary echocardiography. If deep vein thrombosis and/or pulmonary embolism are present, therapy must be started immediately (full heparinization or systemic thrombolysis). The occurrence of deep vein thrombosis with subsequent pulmonary embolism can be reduced by consistent prophylaxis. The risk assessment incorporates exponential and dispositional risk factors. Prophylactic measures include early mobilization, compression stockings and in the highest risk group (radical prostatectomy and cystectomy) medicinal measures, as a rule low molecular weight heparins. Venous thromboembolism prophylaxis following such interventions should be continued postoperatively for 4-5 weeks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23831989     DOI: 10.1007/s00120-013-3231-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  13 in total

1.  Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence.

Authors:  A N Nicolaides; H K Breddin; J Fareed; S Goldhaber; S Haas; R Hull; E Kalodiki; K Myers; M Samama; A Sasahara
Journal:  Int Angiol       Date:  2001-03       Impact factor: 2.789

2.  [Medical principles of thromboembolism prevention].

Authors:  S Haas
Journal:  Langenbecks Arch Chir Suppl Kongressbd       Date:  1998

Review 3.  [Prevalence of clinically silent pulmonary embolism in deep venous thrombosis of the legs].

Authors:  R Pesavento; L Lusiani; A Visonà; A Bonanome; P Zanco; C Perissinotto; A Pagnan
Journal:  Minerva Cardioangiol       Date:  1997 Jul-Aug       Impact factor: 1.347

Review 4.  Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice.

Authors:  A G Turpie
Journal:  Am Heart J       Date:  2001-08       Impact factor: 4.749

5.  A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study.

Authors:  H Riess; S Haas; U Tebbe; H-E Gerlach; C Abletshauser; C Sieder; S Rossol; B Pfeiffer; S M Schellong
Journal:  J Thromb Haemost       Date:  2010-03-09       Impact factor: 5.824

6.  High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism.

Authors:  P Girard; D Musset; F Parent; S Maitre; C Phlippoteau; G Simonneau
Journal:  Chest       Date:  1999-10       Impact factor: 9.410

7.  Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin.

Authors:  H Partsch; W Blättler
Journal:  J Vasc Surg       Date:  2000-11       Impact factor: 4.268

Review 8.  Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.

Authors:  Alexander G G Turpie; Reinhold Kreutz; Juan Llau; Bo Norrving; Sylvia Haas
Journal:  Thromb Haemost       Date:  2012-09-26       Impact factor: 5.249

9.  Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Hirsh; Robert Raschke
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

Review 10.  Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.

Authors:  Morten Schnack Rasmussen; Lars Nannestad Jørgensen; Peer Wille-Jørgensen
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.